Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)AMANDA OLGA MÜLLER, Roger von Moos, BC Pestalozzi et al.|Cancer Research|2019Cited by 2
Differentialdiagnose des pulmonalen Infiltrates nach Pneumothorax-DrainageBeatrix Hoksch, Ralph A. Schmid, Theresia Weber et al.|Der Chirurg|2005Cited by 0
Pulmonales Infiltrat nach PneumothoraxdrainageBeatrix Hoksch, Ralph A. Schmid, Julian Schardt et al.|Der Pneumologe|2005Cited by 0